Sweden · Delayed Price · Currency is SEK Immunovia AB Statistics
Total Valuation
Immunovia AB has a market cap or net worth of SEK 87.18 million. The enterprise value is 55.55 million.
| Market Cap | 87.18M |
| Enterprise Value | 55.55M |
Important Dates
The next confirmed earnings date is Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunovia AB has 672.67 million shares outstanding. The number of shares has increased by 180.08% in one year.
| Current Share Class | 672.67M |
| Shares Outstanding | 672.67M |
| Shares Change (YoY) | +180.08% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 9.26% |
| Owned by Institutions (%) | 12.66% |
| Float | 610.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 71.99 |
| PB Ratio | 3.69 |
| P/TBV Ratio | 5.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 45.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.14.
| Current Ratio | 1.57 |
| Quick Ratio | 1.55 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -426.97% and return on invested capital (ROIC) is -229.45%.
| Return on Equity (ROE) | -426.97% |
| Return on Assets (ROA) | -124.89% |
| Return on Invested Capital (ROIC) | -229.45% |
| Return on Capital Employed (ROCE) | -350.38% |
| Weighted Average Cost of Capital (WACC) | 18.17% |
| Revenue Per Employee | 67,278 |
| Profits Per Employee | -4.91M |
| Employee Count | 18 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.30% in the last 52 weeks. The beta is 2.65, so Immunovia AB's price volatility has been higher than the market average.
| Beta (5Y) | 2.65 |
| 52-Week Price Change | -82.30% |
| 50-Day Moving Average | 0.17 |
| 200-Day Moving Average | 0.20 |
| Relative Strength Index (RSI) | 18.49 |
| Average Volume (20 Days) | 3,023,156 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Immunovia AB had revenue of SEK 1.21 million and -88.34 million in losses. Loss per share was -0.16.
| Revenue | 1.21M |
| Gross Profit | 690,000 |
| Operating Income | -82.81M |
| Pretax Income | -88.34M |
| Net Income | -88.34M |
| EBITDA | -83.22M |
| EBIT | -82.81M |
| Loss Per Share | -0.16 |
Balance Sheet
The company has 34.90 million in cash and 3.27 million in debt, with a net cash position of 31.63 million or 0.05 per share.
| Cash & Cash Equivalents | 34.90M |
| Total Debt | 3.27M |
| Net Cash | 31.63M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 23.64M |
| Book Value Per Share | 0.04 |
| Working Capital | 13.92M |
Cash Flow
| Operating Cash Flow | -77.35M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | -408,000 |
| Net Borrowing | -1.15M |
| Free Cash Flow | -77.35M |
| FCF Per Share | -0.11 |
Margins
| Gross Margin | 56.98% |
| Operating Margin | -6,838.40% |
| Pretax Margin | -7,294.38% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunovia AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -180.08% |
| Shareholder Yield | -180.08% |
| Earnings Yield | -101.33% |
| FCF Yield | -88.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Immunovia AB has an Altman Z-Score of -40.15 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -40.15 |
| Piotroski F-Score | 2 |